GLP-1 based therapies have shown promise in liver diseases e.g. non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.